This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Gepirone Extended-Release in the Treatment of Adult Outpatients With Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study

Robert J. Bielski, MD; Lynn Cunningham, MD; Joseph P. Horrigan, MD; Peter D. Londborg, MD; Ward T. Smith, MD; and Kenneth Weiss, MD

Published: March 18, 2008

Article Abstract

Objective: To evaluate the efficacy and tolerability of extended-release gepirone (gepirone-ER), a 5-HT1A agonist, versus placebo in the treatment of adult outpatients with major depressive disorder (MDD).

Method: A double-blind, randomized, placebo-controlled, parallel-group, 8-week study was conducted from October 2003 to August 2004 in outpatients 18 to 64 years old with moderate-to-severe MDD, as defined by theDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), and a baseline Hamilton Rating Scale for Depression (HAM-D17) total score >= 20. Patients were titrated from 20 to 80 mg/day of gepirone-ER or placebo (most patients received gepirone-ER 60 or 80 mg/day by week 3). The primary outcome measure was baseline-to-endpoint mean change in HAM-D17 total score. Secondary outcome measures included the 28-item version of the HAM-D, HAM-D depressed mood (item 1), Bech Six-Item Scale, Montgomery-Asberg Depression Rating Scale, and Clinical Global Impressions scale.

Results: Significantly greater reductions in HAM-D17 total scores occurred in gepirone-ER-treated patients compared with placebo-treated patients by week 4 (p = .004) and continued through weeks 6 (p = .006) and 8 (p = .032). Secondary outcomes also improved significantly at multiple timepoints, including at endpoint. The most frequently reported adverse events in the gepirone-ER versus placebo groups were dizziness (45% vs. 10%), nausea (36% vs. 13%), and headache (24% vs. 16%). Dizziness occurred most frequently during initial dosing and up-titration.

Conclusions: Gepirone-ER significantly reduced depression symptoms and illness severity in MDD outpatients through the end of the study and was generally well tolerated, confirming previous findings.

Volume: 69

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF